Skip to main content
logo
Novo Nordisk A/S (NONOF)
OTCMKTS · Delayed Price · Currency is USD
57.32
0.00 (0.00%)
Jan 8, 2026, 9:30 AM EST

Revenue

Millions DKK. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 20212011 - 2020
Period Ending
Sep '25 Dec '24 Dec '23 Dec '22 Dec '21 2011 - 2020
Rybelsus Revenue
23.71B23.30B
Log In
Log In
Log In
Upgrade
Ozempic Revenue
129.12B120.34B
Log In
Log In
Log In
Upgrade
Victoza Revenue
4.02B5.48B
Log In
Log In
Log In
Upgrade
Total GLP-1 Revenue
156.85B149.13B
Log In
Log In
Log In
Upgrade
Long-Acting Insulin Revenue
19.21B19.10B
Log In
Log In
Log In
Upgrade
Premix Insulin Revenue
10.67B10.79B
Log In
Log In
Log In
Upgrade
Fast-Acting Insulin Revenue
19.72B18.52B
Log In
Log In
Log In
Upgrade
Human Insulin Revenue
6.02B6.97B
Log In
Log In
Log In
Upgrade
Total Insulin Revenue
55.62B55.37B
Log In
Log In
Log In
Upgrade
Other Diabetes Care Revenue
1.86B2.12B
Log In
Log In
Log In
Upgrade
Total Diabetes Care Revenue
214.33B206.62B
Log In
Log In
Log In
Upgrade
Wegovy Revenue
77.11B58.21B
Log In
Log In
Log In
Upgrade
Saxenda Revenue
4.20B6.94B
Log In
Log In
Log In
Upgrade
Total Obesity Care Revenue
81.31B65.15B
Log In
Log In
Log In
Upgrade
Diabetes & Obesity Care Revenue
295.64B271.76B
Log In
Log In
Log In
Upgrade
Rare Blood Disorders Revenue
12.33B12.14B
Log In
Log In
Log In
Upgrade
Rare Endocrine Disorders Revenue
6.05B4.99B
Log In
Log In
Log In
Upgrade
Other Rare Disease Revenue
1.58B1.51B
Log In
Log In
Log In
Upgrade
Rare Disease Revenue
19.96B18.64B
Log In
Log In
Log In
Upgrade
Revenue (Total)
315.60B290.40B
Log In
Log In
Log In
Upgrade

Revenue by Geography

Millions DKK. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 20212011 - 2020
Period Ending
Sep '25 Dec '24 Dec '23 Dec '22 Dec '21 2011 - 2020
US Revenue
180.79B167.40B
Log In
Log In
Log In
Upgrade
EUCAN Revenue
64.40B57.55B
Log In
Log In
Log In
Upgrade
Emerging Markets Revenue
30.16B29.52B
Log In
Log In
Log In
Upgrade
APAC Revenue
21.05B17.44B
Log In
Log In
Log In
Upgrade
China Revenue
19.20B18.50B
Log In
Log In
Log In
Upgrade
Total International Revenue
134.81B123.00B
Log In
Log In
Log In
Upgrade
Revenue (Other)
-134.81B-123.00B
Log In
Log In
Log In
Upgrade
Revenue (Total)
315.60B290.40B
Log In
Log In
Log In
Upgrade

Revenue by Geography 2

Millions DKK. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 20212011 - 2020
Period Ending
Sep '25 Dec '24 Dec '23 Dec '22 Dec '21 2011 - 2020
US Revenue (Pre-FY2024 Reporting)
156.42B167.40B
Log In
Log In
Log In
Upgrade
Other North American Operations (NAO) Revenue
-10.77B
Log In
Log In
Log In
Upgrade
Total North American Operations (NAO) Revenue
-178.17B
Log In
Log In
Log In
Upgrade
EMEA Revenue
-60.40B
Log In
Log In
Log In
Upgrade
China Revenue (Pre-FY2024 Reporting)
19.20B18.50B
Log In
Log In
Log In
Upgrade
Rest of World Revenue
-33.33B
Log In
Log In
Log In
Upgrade
Revenue (Total)
315.60B290.40B
Log In
Log In
Log In
Upgrade

EBIT

Millions DKK. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 20212011 - 2020
Period Ending
Sep '25 Dec '24 Dec '23 Dec '22 Dec '21 2011 - 2020
Diabetes & Obesity Care Operating Profit
131.44B127.72B
Log In
Log In
Log In
Upgrade
Rare Disease Operating Profit
1.22B620.00M
Log In
Log In
Log In
Upgrade
Operating Income (Total)
132.66B128.34B
Log In
Log In
Log In
Upgrade
Updated Sep 30, 2025. Data Source: Fiscal.ai.